{"id":"h2-receptor-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gynecomastia (with long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs competitively inhibit histamine binding to H2 receptors, which normally stimulate gastric acid production. By blocking this pathway, H2 antagonists decrease both basal and stimulated acid secretion, raising gastric pH and allowing ulcers and acid-related conditions to heal. They are used for peptic ulcer disease, gastroesophageal reflux disease (GERD), and other acid-related disorders.","oneSentence":"H2 receptor antagonists block histamine H2 receptors on gastric parietal cells to reduce stomach acid secretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:50.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peptic ulcer disease"},{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Zollinger-Ellison syndrome"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT06393374","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-24","conditions":"Triple-Negative Breast Cancer","enrollment":1530},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06637423","phase":"PHASE1, PHASE2","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":32},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT07408271","phase":"","title":"The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-24","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication Antibiotic","enrollment":83},{"nctId":"NCT06074588","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-12","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":556},{"nctId":"NCT07089420","phase":"","title":"ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects","status":"RECRUITING","sponsor":"American Laboratory Products Company","startDate":"2025-07-07","conditions":"IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD)","enrollment":120},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06460961","phase":"PHASE1","title":"A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-14","conditions":"Neoplasm Metastasis","enrollment":168},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT07171619","phase":"PHASE1","title":"Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat","status":"RECRUITING","sponsor":"SpringWorks Therapeutics, Inc.","startDate":"2025-09-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT06789172","phase":"PHASE1","title":"A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Epkin","startDate":"2025-01-23","conditions":"Solid Tumours, Sarcoma, HNSCC","enrollment":166},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT07109284","phase":"PHASE2","title":"SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-09","conditions":"ER+HER2- Breast Cancer","enrollment":55},{"nctId":"NCT06241183","phase":"PHASE4","title":"Famotidine and Antacids for Treatment of Dyspepsia","status":"RECRUITING","sponsor":"Stony Brook University","startDate":"2023-11-09","conditions":"Dyspepsia, GERD, Acid Reflux","enrollment":80},{"nctId":"NCT04433208","phase":"NA","title":"Dietary Supplement With and Without a Probiotic","status":"COMPLETED","sponsor":"Prolacta Bioscience","startDate":"2020-03-13","conditions":"Healthy Adult Subjects","enrollment":62},{"nctId":"NCT04600466","phase":"","title":"Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-01-22","conditions":"Gastric Cancer","enrollment":150},{"nctId":"NCT06778824","phase":"NA","title":"Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","status":"RECRUITING","sponsor":"Hualien Tzu Chi General Hospital","startDate":"2024-04-02","conditions":"Gut-Brain Disorders, GERD Without Erosive Esophagitis","enrollment":610},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT04834752","phase":"","title":"Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2021-05-01","conditions":"COVID-19","enrollment":400000},{"nctId":"NCT05338502","phase":"PHASE1","title":"Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-08","conditions":"Healthy","enrollment":20},{"nctId":"NCT03554291","phase":"PHASE2","title":"Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-05-01","conditions":"Pulmonary Arterial Hypertension, Right Heart Failure","enrollment":80},{"nctId":"NCT05574504","phase":"PHASE2","title":"Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy","status":"WITHDRAWN","sponsor":"AdventHealth","startDate":"2023-05-08","conditions":"Metastatic Cancer, Urothelial Carcinoma","enrollment":""},{"nctId":"NCT01209455","phase":"NA","title":"Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2011-01-03","conditions":"Poisoning","enrollment":24},{"nctId":"NCT03747991","phase":"","title":"How Reflux Medications Affect the Microbiome of Infants","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2018-08-13","conditions":"GERD, Dysbiosis","enrollment":12},{"nctId":"NCT04450134","phase":"NA","title":"Histamine H1/H2 Receptors and Training Adaptations","status":"COMPLETED","sponsor":"University Ghent","startDate":"2019-10-02","conditions":"Exercise Training, Physical Activity","enrollment":19},{"nctId":"NCT04990388","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-10-18","conditions":"Glycogen Storage Disease Type III","enrollment":9},{"nctId":"NCT05131555","phase":"NA","title":"Influence of Endurance Exercise and Histamine Receptors on the Gene Expression in Skeletal Muscle","status":"COMPLETED","sponsor":"University Ghent","startDate":"2021-08-16","conditions":"Exercise, Histamine","enrollment":14},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT03728179","phase":"PHASE1","title":"RACIN in Patients With Advanced TIL-negative Solid Tumors","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2019-01-16","conditions":"Solid Tumor, Adult","enrollment":40},{"nctId":"NCT04840615","phase":"PHASE1","title":"Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-11","conditions":"Mesothelioma","enrollment":2},{"nctId":"NCT02016820","phase":"NA","title":"Effect of Acid Suppression Medication on Pediatric Microbiome","status":"TERMINATED","sponsor":"Columbia University","startDate":"2014-11","conditions":"Clostridium Difficile Infection","enrollment":7},{"nctId":"NCT05284084","phase":"NA","title":"Prevention of Broncho-aspiration (BA) in Adult Subjects During Their ICU Stay","status":"COMPLETED","sponsor":"Marshall University","startDate":"2021-08-03","conditions":"Bronchial Aspiration","enrollment":159},{"nctId":"NCT03541408","phase":"NA","title":"Preventative Delirium Protocol in Elderly Patients","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2016-05-01","conditions":"Delirium","enrollment":263},{"nctId":"NCT01649947","phase":"PHASE2","title":"Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2011-12-23","conditions":"Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer","enrollment":32},{"nctId":"NCT03667703","phase":"PHASE4","title":"Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2019-03-10","conditions":"Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer","enrollment":70},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT03619408","phase":"","title":"Management of Esophagitis Following Repair of Esophageal Atresia","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2019-02-01","conditions":"Esophageal Atresia, Esophagitis","enrollment":50},{"nctId":"NCT03050866","phase":"PHASE2","title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2017-02-21","conditions":"Circulating Tumor Cell, Metastatic Prostate Cancer","enrollment":140},{"nctId":"NCT02556619","phase":"NA","title":"Randomized Control Trial (RCT) of Early Palliative Care for HCC","status":"UNKNOWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-04-02","conditions":"Carcinoma, Hepatocellular","enrollment":72},{"nctId":"NCT04540965","phase":"PHASE1","title":"Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2020-09-22","conditions":"Drug Interaction","enrollment":22},{"nctId":"NCT02906670","phase":"PHASE1, PHASE2","title":"Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies","status":"TERMINATED","sponsor":"Symphogen A/S","startDate":"2016-11-01","conditions":"Oncology","enrollment":32},{"nctId":"NCT04530851","phase":"NA","title":"Compare Outcome of Enhanced Recovery After Cesarean Surgery and Conventional Care","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-01-15","conditions":"To Determine Whether ERAS Can Reduce Length of Stay in Pregnant Women After Cesarean Section","enrollment":80},{"nctId":"NCT02551744","phase":"NA","title":"Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-07","conditions":"Peptic Ulcer","enrollment":101},{"nctId":"NCT03293225","phase":"","title":"Efficacy of Antihistamine Dosing-up and add-on Treatment With H2-receptor Antagonist","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2017-08-24","conditions":"Chronic Urticaria","enrollment":110},{"nctId":"NCT04003350","phase":"NA","title":"The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Rothman Institute Orthopaedics","startDate":"2017-12-21","conditions":"Osteo Arthritis Knee","enrollment":216},{"nctId":"NCT02418312","phase":"NA","title":"Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-01","conditions":"Peptic Ulcer","enrollment":228},{"nctId":"NCT01332630","phase":"PHASE2","title":"TPI 287 in Breast Cancer Metastatic to the Brain","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-08-16","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT01019434","phase":"PHASE2","title":"Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2009-10","conditions":"Brain and Central Nervous System Tumors","enrollment":111},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":24},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT03123796","phase":"","title":"Effects of Proton Pump Inhibitors on Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2016-12","conditions":"Transplant Dysfunction, Magnesium Disorder","enrollment":300},{"nctId":"NCT02700087","phase":"NA","title":"In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2016-02","conditions":"Laryngomalacia, Acid Reflux, Stridor","enrollment":""},{"nctId":"NCT02655458","phase":"PHASE1","title":"Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma","status":"COMPLETED","sponsor":"Hearn Jay Cho","startDate":"2016-01","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT01042704","phase":"PHASE1","title":"Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Robert Redner, MD","startDate":"2008-02","conditions":"Myeloma","enrollment":29},{"nctId":"NCT00001241","phase":"","title":"Treatment of Zollinger-Ellison Syndrome","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1989-01-27","conditions":"Zollinger Ellison Syndrome","enrollment":""},{"nctId":"NCT00924911","phase":"PHASE1","title":"Relative Bioavailability Study in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-27","conditions":"Infections, Bacterial","enrollment":20},{"nctId":"NCT01408186","phase":"PHASE3","title":"ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2011-01","conditions":"Upper Gastrointestinal Bleeding","enrollment":264},{"nctId":"NCT02441894","phase":"PHASE4","title":"Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04","conditions":"Prostate Cancer","enrollment":21},{"nctId":"NCT00657228","phase":"NA","title":"Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department","status":"WITHDRAWN","sponsor":"University of Missouri, Kansas City","startDate":"2009-12","conditions":"Anaphylaxis","enrollment":""},{"nctId":"NCT00950339","phase":"PHASE4","title":"Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2009-08","conditions":"Coronary Heart Disease, GI Bleeding","enrollment":63},{"nctId":"NCT02555852","phase":"","title":"Proton Pump Inhibitors and Risk of Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2011-09","conditions":"Gastroesophageal Reflux Disease (GERD), Community-acquired Pneumonia","enrollment":4238504},{"nctId":"NCT02541643","phase":"","title":"Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma","status":"NO_LONGER_AVAILABLE","sponsor":"Sundar Jagannath","startDate":"","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02097329","phase":"PHASE1","title":"Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Healthy","enrollment":27},{"nctId":"NCT01264939","phase":"PHASE3","title":"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-02","conditions":"Chronic Idiopathic Urticaria","enrollment":336},{"nctId":"NCT01001221","phase":"PHASE1, PHASE2","title":"Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-11","conditions":"Neoplasms, Malignant","enrollment":19},{"nctId":"NCT00708149","phase":"PHASE4","title":"Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-06","conditions":"Respiratory Failure","enrollment":120},{"nctId":"NCT00972205","phase":"NA","title":"Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12","conditions":"Cervical, Ovarian, Lung","enrollment":12},{"nctId":"NCT00551473","phase":"PHASE1","title":"Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Gastroesophageal Reflux Disease, Reflux, Gastroesophageal","enrollment":18},{"nctId":"NCT01087021","phase":"PHASE1","title":"Effect of Cabazitaxel on the QTc Interval in Cancer Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-03","conditions":"Neoplasms, Malignant","enrollment":45},{"nctId":"NCT00229424","phase":"PHASE3","title":"Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2005-04","conditions":"Gastroesophageal Reflux","enrollment":325},{"nctId":"NCT01179724","phase":"NA","title":"Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-07","conditions":"Delayed Bleeding","enrollment":206},{"nctId":"NCT00557453","phase":"","title":"The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2008-04","conditions":"Acute Cholecystitits","enrollment":120},{"nctId":"NCT00120315","phase":"PHASE4","title":"Proton Pump Inhibitor Treatment Stop","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2003-12","conditions":"Dyspepsia","enrollment":171},{"nctId":"NCT00247715","phase":"NA","title":"Comparison of a \"Step-Up\" Versus a \"Step-Down\" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2003-10","conditions":"Dyspepsia, Gastrointestinal Diseases","enrollment":664}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2499,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Famotidine","H2RA"],"phase":"phase_3","status":"active","brandName":"H2 Receptor Antagonist","genericName":"H2 Receptor Antagonist","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"H2 receptor antagonists block histamine H2 receptors on gastric parietal cells to reduce stomach acid secretion. Used for Peptic ulcer disease, Gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}